TY - JOUR
T1 - Hsp60, amateur chaperone in amyloid-beta fibrillogenesis
AU - Mangione, Maria Rosalia
AU - Vilasi, Silvia
AU - Marino, Claudia
AU - Librizzi, Fabio
AU - Canale, Claudio
AU - Spigolon, Dario
AU - Bucchieri, Fabio
AU - Fucarino, Alberto
AU - Passantino, Rosa
AU - Cappello, Francesco
AU - Bulone, Donatella
AU - San Biagio, Pier Luigi
N1 - Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background Molecular chaperones are a very special class of proteins that play essential roles in many cellular processes like folding, targeting and transport of proteins. Moreover, recent evidence indicates that chaperones can act as potentially strong suppressor agents in Alzheimer's disease (AD). Indeed, in vitro experiments demonstrate that several chaperones are able to significantly slow down or suppress aggregation of Aβ peptide and in vivo studies reveal that treatment with specific chaperones or their overexpression can ameliorate some distinct pathological signs characterizing AD. Methods Here we investigate using a biophysical approach (fluorescence, circular dichroism (CD), transmission electron (TEM) and atomic force (AFM) microscopy, size exclusion chromatography (SEC)) the effect of the human chaperonin Hsp60 on Aβ fibrillogenesis. Results We found that Hsp60 powerfully inhibits Aβ amyloid aggregation, by closing molecular pathways leading to peptide fibrillogenesis. Conclusions We observe that Hsp60 inhibits Aβ aggregation through a more complex mechanism than a simple folding chaperone action. The action is specifically directed toward the early oligomeric species behaving as aggregation seeds for on-pathway amyloid fibrillogenesis.
AB - Background Molecular chaperones are a very special class of proteins that play essential roles in many cellular processes like folding, targeting and transport of proteins. Moreover, recent evidence indicates that chaperones can act as potentially strong suppressor agents in Alzheimer's disease (AD). Indeed, in vitro experiments demonstrate that several chaperones are able to significantly slow down or suppress aggregation of Aβ peptide and in vivo studies reveal that treatment with specific chaperones or their overexpression can ameliorate some distinct pathological signs characterizing AD. Methods Here we investigate using a biophysical approach (fluorescence, circular dichroism (CD), transmission electron (TEM) and atomic force (AFM) microscopy, size exclusion chromatography (SEC)) the effect of the human chaperonin Hsp60 on Aβ fibrillogenesis. Results We found that Hsp60 powerfully inhibits Aβ amyloid aggregation, by closing molecular pathways leading to peptide fibrillogenesis. Conclusions We observe that Hsp60 inhibits Aβ aggregation through a more complex mechanism than a simple folding chaperone action. The action is specifically directed toward the early oligomeric species behaving as aggregation seeds for on-pathway amyloid fibrillogenesis.
KW - Alzheimer's disease treatment
KW - Amyloid aggregation
KW - Chaperonin
KW - Inhibition mechanisms
KW - Molecular chaperones
UR - http://www.scopus.com/inward/record.url?scp=84984645423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984645423&partnerID=8YFLogxK
U2 - 10.1016/j.bbagen.2016.07.019
DO - 10.1016/j.bbagen.2016.07.019
M3 - Article
C2 - 27474204
AN - SCOPUS:84984645423
SN - 0304-4165
VL - 1860
SP - 2474
EP - 2483
JO - Biochimica et Biophysica Acta - General Subjects
JF - Biochimica et Biophysica Acta - General Subjects
IS - 11
ER -